Be a part of 6th International Meeting on Breast Cancer & Therapies

Precision Oncology and Personalized Breast Cancer Treatment: Molecular profiling, genomic testing, biomarker-driven therapy, individualized treatment strategies, and precision medicine.
Breast Cancer Screening, Early Detection and Diagnosis: Mammography, ultrasound, MRI, digital breast imaging, early detection strategies, diagnostic pathways, and risk assessment.
Breast Cancer Genomics, Molecular Biology and Biomarkers: Tumor genetics, molecular subtypes, hereditary cancer genes, liquid biopsy, circulating tumor DNA, and predictive biomarkers.
Targeted Therapies and Novel Therapeutic Approaches: HER2-directed therapies, CDK4/6 inhibitors, antibody-drug conjugates, PI3K/AKT pathway inhibitors, and emerging treatments.
Immunotherapy and Immune-Based Strategies in Breast Cancer: Immune checkpoint inhibitors, tumor microenvironment, biomarkers of response, combination therapies, and emerging immunotherapeutic approaches.
Triple-Negative Breast Cancer: New Therapies and Challenges: TNBC biology, targeted approaches, immunotherapy, antibody-drug conjugates, treatment resistance, and clinical trial developments.
Breast Cancer Surgery, Reconstruction and Minimally Invasive Techniques: Breast-conserving surgery, mastectomy, sentinel lymph node procedures, oncoplastic surgery, reconstruction, and surgical innovations.
Radiation Oncology and Advances in Breast Cancer Radiotherapy: Precision radiotherapy, hypofractionation, image-guided radiation, proton therapy, partial-breast irradiation, and treatment planning.
Metastatic and Advanced Breast Cancer Management: Bone, liver, lung and brain metastases, treatment sequencing, resistance mechanisms, novel systemic therapies, and multidisciplinary care.
Clinical Trials, Drug Development and Treatment Resistance: Early-phase trials, translational research, novel drug development, real-world evidence, resistance mechanisms, and combination therapies.
Breast Cancer Survivorship, Rehabilitation and Quality of Life: Long-term follow-up, recurrence prevention, rehabilitation, psychosocial care, sexual health, fertility, lifestyle, and survivorship programs.
Breast Cancer Prevention, Risk Reduction and Global Health Equity: Genetic counseling, high-risk populations, lifestyle interventions, prevention strategies, disparities in care, access to treatment, and global breast cancer initiatives.

Breast cancer remains the most commonly diagnosed cancer among women worldwide and continues to represent a major public health challenge. According to the World Health Organization (WHO), more than 2.3 million women are diagnosed with breast cancer annually, and nearly 685,000 deaths are reported each year. Rising incidence rates, combined with increasing survivorship, underscore the urgent need for advancements in early detection, precision medicine, and accessible treatment strategies.

The global breast cancer therapeutics market is experiencing rapid growth, driven by advances in targeted therapy, immunotherapy, precision diagnostics, and digital health solutions. In 2023, the breast cancer treatment market was valued at approximately USD 28 billion and is projected to reach USD 55–60 billion by 2030, with a compound annual growth rate (CAGR) of over 10%. Emerging markets in Asia-Pacific and Latin America are also witnessing accelerated adoption of innovative therapies, fueled by government initiatives, awareness programs, and improved healthcare infrastructure.

Key industry trends include the integration of AI and big data in oncology, increased focus on triple-negative breast cancer (TNBC) therapies, growing importance of biosimilars, and a shift toward personalized medicine. Additionally, supportive care and survivorship management are becoming integral parts of treatment strategies, highlighting the holistic approach needed for long-term patient well-being.

The 5th International Meeting on Breast Cancer & Therapies in Paris will provide an essential platform for discussing these market dynamics, fostering collaborations between academia, healthcare providers, policymakers, and industry leaders to shape the future of breast cancer care globally.